Kristi Rosa | Authors


Percentage of Actionable Mutations in Prostate Cancer Underscores Importance of Testing

November 12, 2022

During a presentation, Emmanuel S. Antonarakis, MD explained that homologous repair mutations and mismatch mutations in prostate cancer have therapeutic implications in the context of PARP inhibitors and PD-1 inhibitors.

Regorafenib Then Nivolumab Sequence Is Tolerable After First-Line HCC Treatment

October 14, 2022

Data presented during the 2022 International Liver Cancer Association Conference showed that less than one-third of patients with hepatocellular carcinoma who received regorafenib followed by nivolumab experienced grade 3 or 4 treatment-related adverse events.

Lenvatinib/Pembrolizumab Appears Safe in Metastasized Anaplastic Thyroid Carcinoma

September 13, 2022

Data presented during the 2022 ESMO Congress showed lenvatinib plus pembrolizumab to elicit an objective response rate of 34.3% after 3 months in evaluable patients, meeting the primary end point of the phase 2 ATLEP trial.

Adjuvant Osimertinib Shows 77% Reduction in Disease Recurrence Risk in Early-Stage EGFR-Mutated NSCLC

September 11, 2022

Updated findings from the phase 3 ADAURA trial showed a significant disease-free survival improvement with the use of adjuvant osimertinib compared with placebo in patients with EGFR-mutated, stage I to IIIA non–small cell lung cancer.

First-line Olaparib Triplet Improves Outcomes in mCRPC

September 11, 2022

Signs of an overall survival benefit were seen with a regimen of olaparib plus abiraterone acetate and prednisone or prednisolone as a first-line therapy for patients with metastatic castration-resistant prostate cancer, according to updated data from the phase 3 PROpel trial.